Clinical Trial

ESCALATion of Medical Therapy Following Multimodality Plaque Evaluation in High-risk Chronic Coronary Syndromes

Study acronym: ESCALATE
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 21, 2024 (before its estimated October 5, 2025 completion). Its status may not reflect the trial's current state.
Summary
ESCALATE will provide a thorough investigation of how anti-inflammatory therapy, with low-dose colchicine, affects patients with stable coronary artery disease. Using traditional clinical risk factors and multimodality intracoronary imaging, the investigators will identify patients with the greatest clinical risk. Participants will undergo repeat multimodality intracoronary imaging assessment at 6 months to measure the impact once-daily low-dose colchicine therapy on the structure and function of coronary arteries. This study will provide valuable insights into how anti-inflammatory therapies, such as colchicine, may improve outcomes in patients with coronary artery disease.
Trial Details
NCT Number NCT06469528
Lead Sponsor King's College Hospital NHS Trust
Collaborators: King's College London
Conditions Coronary Artery Disease
Enrollment 50 participants
Start Date 2024-06-24
Primary Completion 2025-10-05 (estimated)
Study Completion 2026-10-05 (estimated)
Updated on ClinicalTrials.gov 2024-06-21